CN101007014B - 一种复方葛根素制剂 - Google Patents
一种复方葛根素制剂 Download PDFInfo
- Publication number
- CN101007014B CN101007014B CN200610049229XA CN200610049229A CN101007014B CN 101007014 B CN101007014 B CN 101007014B CN 200610049229X A CN200610049229X A CN 200610049229XA CN 200610049229 A CN200610049229 A CN 200610049229A CN 101007014 B CN101007014 B CN 101007014B
- Authority
- CN
- China
- Prior art keywords
- puerarin
- preparation
- injection
- compound
- moschus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 74
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 49
- 150000001875 compounds Chemical class 0.000 title claims abstract description 47
- 239000003814 drug Substances 0.000 claims description 21
- 239000007924 injection Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 20
- 238000002156 mixing Methods 0.000 claims description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 238000005516 engineering process Methods 0.000 claims description 8
- 238000005303 weighing Methods 0.000 claims description 8
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000008215 water for injection Substances 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 230000008030 elimination Effects 0.000 claims description 3
- 238000003379 elimination reaction Methods 0.000 claims description 3
- 239000004576 sand Substances 0.000 claims description 3
- 238000003556 assay Methods 0.000 claims description 2
- 238000007689 inspection Methods 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 241000972155 Moschus Species 0.000 claims 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 abstract description 26
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 14
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 14
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 13
- 239000000463 material Substances 0.000 abstract description 3
- 239000000470 constituent Substances 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 244000153234 Hibiscus abelmoschus Species 0.000 description 24
- 239000006187 pill Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008187 granular material Substances 0.000 description 9
- 238000003756 stirring Methods 0.000 description 8
- 230000008499 blood brain barrier function Effects 0.000 description 7
- 210000001218 blood-brain barrier Anatomy 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 206010006148 Brain stem ischaemia Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000000763 evoking effect Effects 0.000 description 5
- 235000019359 magnesium stearate Nutrition 0.000 description 5
- 239000005720 sucrose Substances 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 210000000133 brain stem Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 4
- 239000000700 radioactive tracer Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 206010042772 syncope Diseases 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 238000012449 Kunming mouse Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 230000001476 alcoholic effect Effects 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 230000002490 cerebral effect Effects 0.000 description 3
- 229960004756 ethanol Drugs 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000002385 vertebral artery Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 229920003081 Povidone K 30 Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000010513 Stupor Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002826 coolant Substances 0.000 description 2
- 239000006184 cosolvent Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002439 hemostatic effect Effects 0.000 description 2
- 238000009413 insulation Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960002275 pentobarbital sodium Drugs 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- -1 polyoxyethylene stearate Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 241000123611 Dipterocarpaceae Species 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 206010048010 Withdrawal syndrome Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000003461 brachial plexus Anatomy 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 210000003109 clavicle Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- DUWWHGPELOTTOE-UHFFFAOYSA-N n-(5-chloro-2,4-dimethoxyphenyl)-3-oxobutanamide Chemical compound COC1=CC(OC)=C(NC(=O)CC(C)=O)C=C1Cl DUWWHGPELOTTOE-UHFFFAOYSA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000011121 sodium hydroxide Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000001898 sternoclavicular joint Anatomy 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种治疗心脑血管疾病的复方制剂,具体地说涉及一种复方葛根素制剂。一种复方葛根素制剂,其特征在于包括下述重量份的药物成分:葛根素1份,冰片0.1~2份,与药学上可接受的药物载体或辅料混合,制成复方制剂。本发明具有有效成分含量明确,药物制剂安全、有效、可控的特点,是一种配伍较好,生物利用度较高可用于防治心脑血管疾病的复方制剂。
Description
技术领域
本发明涉及一种治疗心脑血管疾病的复方制剂,具体地说涉及一种复方葛根素制剂。
背景技术
心脑血管疾病是常见病、多发病,是人类的第一杀手。由于心脑血管疾病具有慢性、突发性等特点,严重时可致人死亡,用来治疗心脑血管疾病的药物常常为化学类药物,但是此类药物常常会产生副反应(如胃肠道反应),毒性反应(如损害循环、呼吸及神经系统功能等毒性)停药反应等一系列的不良反应;所以人们越来越倚重于中成药来治疗心脑血管疾病。但是中成药使用传统的口服制剂,存在溶散时限长、溶出度低、吸收较差、生物利用度较低等问题。因此研制一种可用于抢救又不影响日常使用的药物,是解决方法之一。滴丸、口崩片、注射剂等剂型,具有作用速度快、生物利用度高、临床效果好等特点,符合防治心脑血管疾病的临床要求。如中国专利申请(200310122493.8)葛根素滴丸及其制备方法,该专利申请以葛根素为原料,按照比例加入一定量的聚乙二醇并混合均匀,将混合物料加热至熔融,充分搅拌使均匀,置入专用的滴丸机,以适当的速度,滴入冷凝剂中而成。该专利申请虽然向广大患者和医务工作者提供一种对心血管疾病具有快速释药,快速显效,毒副作用小,有效成分明确的葛根素滴丸,但是该专利申请忽略了人体由于存在血脑屏障,药物很难进入脑组织的问题,所以该专利申请对脑血管疾病的治疗还是不甚理想,并不能符合所有防治心脑血管疾病的临床要求。
发明内容
本发明的目的在于提供一种不仅对心血管疾病的疗效较好、起效快、生物利用度高、而且对脑血管疾病的疗效较好、起效快、生物利用度高的复方葛根素制剂。
本发明的上述技术目的是通过以下技术方案解决的:一种复方葛根素制剂,其特征在于包括下述重量份的药物成分:葛根素1份,冰片0.1~2份,与药学上可接受的药物载体或辅料混合,制成复方制剂。
本发明的上述技术方案其特征还在于:所述的药物成分中还可以含有麝香0.05~1份,与药学上可接受的药物载体或辅料混合,制成复方制剂。
本发明的上述技术方案其特征还在于:所述的剂型包括药学上允许的所有剂型。
本发明的上述技术方案其特征还在于:优选剂型为注射剂、片剂、丸剂、滴丸剂、胶囊、颗粒剂和口服液。
本发明所述的复方葛根素制剂组份中,葛根素系由豆科植物野葛的干燥根中提取、分离得到的8-β-D-葡萄吡喃糖-4’,7-二羟基异黄酮,按干燥品计算,含C21H20O9应大于80%。葛根素为血管扩张药,对冠状动脉有扩张作用,可降低心肌耗氧量,并具有活血化瘀、改善微循环的作用,主要用于冠心病、急性心绞痛、心肌梗塞、视网膜动静脉阻塞,突发性耳聋等病证。
本发明所述的复方葛根素制剂组份中,冰片为龙脑香料常绿乔木香树树脂的加工品,或以菊科植物艾纳香为原料制成的艾片,和以松节油为原料制成的机制冰片,含C10H18O应大于55%。冰片为芳香开窍药,具有开窍醒神、清热止痛的作用。用于热病神昏、惊厥、中风痰厥、气郁暴厥、中恶昏迷等病证。
本发明所述的复方葛根素制剂组份中,麝香为鹿科动物林麝、马麝或原麝成熟雄体香囊中的干燥分泌物,由于天然麝香来源较困难,现主要采用人工麝香。其具有开窍醒神、活血通经、消肿止痛的作用,主要用于热病神昏、中风痰厥、气郁暴厥、中恶昏迷、心腹暴痛等病症。
在葛根素制剂中加入冰片、麝香,心脑血管病患者在用药后,其症状在很短的时间内会得到有效的控制;冰片是一味常用的中药,经研究发现具有“芳香走窜、引药上行”之功效。通常情况下,药物在脑组织浓度一般较低,这是由于血脑屏障所致。一般药物如果不能通过血脑屏障,就很难达到有效的血药浓度,生物利用度非常低。冰片不仅自身能通过血脑屏障,还能够增加血脑屏障的通透性、促使其他药物通过血脑屏障进入脑组织。在葛根素制剂中加入冰片,可以促使葛根素通过血脑屏障到达病变部位,增强了药物的疗效,提高了药物到达病变部位的速度,这符合心脑血管疾病的治疗要求。而冰片经常与麝香配伍使用,这是因为麝香的药理作用比冰片强,而且麝香具有镇痛,起到快速治疗和减轻诱发心脑血管疾病发作的病变症状,减少心脑血管疾病发作的机会。
本发明所述的复方葛根素制剂,不但明确了该制剂所含有的药物成分,还给出了三种药物的配伍比例,较好地解决了药物制剂的可控性、安全性、有效性。
作为优选,所述的复方葛根素制剂,其特征在于包括下述重量份的药物成分:葛根素1份,冰片0.3~1份,与药学上可接受的药物载体或辅料混合,制成复方制剂。
在上述的复方葛根素制剂中,其特征在于所述的药物成分中还可以含有麝香0.05~1份,与药学上可接受的药物载体或辅料混合,制成复方制剂。
所述的复方葛根素制剂,还包括药学上可接受的药物辅料。
所述的药学上可接受的药物辅料可以是滴丸基质、等渗剂、缓冲剂、支撑剂、崩解剂、助溶剂、防腐剂、矫味剂、助流剂、填充剂中的一种或多种。
所述的滴丸基质可以是聚乙二醇4000、聚乙二醇6000、泊洛沙姆、硬脂酸聚烃氧(40)酯、明胶、硬脂酸、单硬脂酸甘油酯、氢化甘油酯中的一种或多种。
所述的等渗剂可以是氯化钠、葡萄糖、木糖醇、山梨醇、甘露醇、果糖小的一种或一种以上。
所述的缓冲剂可以是亚硫酸钠、亚硫酸氢钠、焦亚硫酸钠、碳酸钠、碳酸氢钠、氢氧化钠、乳酸、盐酸、醋酸中的一种或一种以上。
所述的支撑剂可以是山梨醇、甘露醇、右旋糖酐中的一种或一种以上。
所述的崩解剂可以是羧甲基淀粉钠、淀粉、微晶纤维素、羧甲基纤维素钠的一种或一种以上。
所述的助溶剂可以是羟丙基倍他环糊精、乙醇、丙二醇、聚乙二醇、甘油、苯甲酸苄酯、二甲基乙酰胺的一种或二种。
所述的防腐剂可以是山梨酸、苯甲酸、丙酸的一种或一种以上。
所述的矫味剂可以是蜂蜜、单糖浆、甘草甜素、甜菊苷、蔗糖的一种或一种以上。
所述的助流剂可以是微粉硅胶、硬脂酸钠、滑石粉的一种或一种以上。
所述的填充剂可以是淀粉、糊精、乳糖、磷酸氢钙中的一种或一种以上。
本发明经过毒理试验结果如下:
(1)急性毒性试验:昆明小鼠每日四次灌胃本发明的复方葛根素制剂(最大浓度0.40g/ml,最大体积50ml/(kg·次·d),剂量为65g/(kg·d))相当于临床日公斤剂量(0.2g/(kg·d)的325倍,观察1周无1只昆明小鼠死亡,未出现毒性反应,本发明的复方葛根素制剂急性毒性反应极小,临床应用剂量安全。
(2)长期毒性试验:大鼠连续灌胃本发明的复方葛根素制剂5g/(kg·d)、18g/(kg·d)、30g/(kg·d),分别相当于临床日公斤剂量(0.2g/(kg·d)的25倍、90倍、150倍。给药12周后,对脏器系数、血象及肝、肾功能等生化指标检测未见异常;对组织切片病理学检查也未发现异常。证明本发明的复方葛根素制剂无延续性毒性反应,临床所用剂量是安全的。
因此,本发明具有有效成分含量明确,药物制剂安全、有效、可控的特点,是一种配伍较好,生物利用度较高可用于防治心脑血管疾病的复方制剂。
具体实施方式
下面通过具体实施例,对本发明的技术方案作进一步具体的说明。但本发明不仅仅限于这些实施例
实施例1:复方葛根素滴丸(A)制备方法
处方:葛根素 300.00g
冰片 100.00g
麝香 50.00g
聚乙二醇4000 400.00g
制成 10000粒
制备方法:取处方量的聚乙二醇4000,熔融;取无水乙醇350mL,加入葛根素、冰片,麝香搅拌使溶;将药液和熔融的聚乙二醇4000混匀,持续搅拌,挥去乙醇,置于已预热的滴丸机中,90℃保温,以甲基硅油作为冷却剂滴制成丸,即得。
实施例2:复方葛根素滴丸(B)制备方法
处方:葛根素 250.00g
冰片 125.00g
聚乙二醇6000 430.00g
制成 10000粒
制备方法:取处方量的聚乙二醇6000,熔融;取无水乙醇300mL,加入葛根素、冰片,搅拌使溶;将药液和熔融的聚乙二醇6000混匀,持续搅拌,挥去乙醇,置于已预热的滴丸机中,88℃保温,以甲基硅油作为冷却剂滴制成丸,即得。
实施例3:复方葛根素注射剂的制备
一、处方
葛根素 200g
麝香 30g
羟丙基倍他环糊精 15g
制成 1000支
二、制备工艺
称取麝香30g,加入羟丙基倍他环糊精15g助溶,加入葛根素200g混匀,加入注射用水至8000ml,温热溶解,加入活性炭脱色,去除热源,用砂棒滤去活性炭,加入注射用水至10000ml,调节pH值为6.0~7.0,检测其含量,合格时,经0.22μm微孔滤膜精滤,罐装于10ml安瓶中,灭菌30分钟,冷却后进行灯检,再经检验合格后,得到水针成品。
实施例4:复方葛根素粉针剂的制备
一、处方
葛根素 150g
冰片 100g
麝香 50g
羟丙基倍他环糊精 50g
甘露醇 50g
制成 1000瓶
二、制备工艺
称取冰片100g、麝香30g,加入羟丙基倍他环糊精50g助溶,加入葛根素150g混匀,加入注射用水至1600ml,加入甘露醇50g,温热溶解,搅拌均匀,加入活性炭脱色,去除热源,用砂棒滤去活性炭,加入注射用水至2000ml,调节pH值为6.0~7.5。用0.22μm微孔滤膜过滤,罐装于洗净的管制瓶中,置冻干机冷冻干燥,真空落盖,得到冻干粉针成品1000瓶。
实施例5:复方葛根素片的制备
一、:处方
葛根素 200g
麝香 100g
冰片 50g
乳糖 80g
羧甲基纤维素钠 20g
淀粉 适量
硬脂酸镁 适量
制成 1000片
二、制备工艺
称取葛根素200g,麝香100g,冰片50g,乳糖80g,羧甲基纤维素钠20g,混匀,用10%淀粉浆制成软材,过筛制粒,60℃干燥,整粒,加入硬脂酸镁适量,与颗粒混匀,压片,即得成品1000片。
实施例6:复方葛根素口服液的制备
一、处方:
葛根素 200g
麝香 100g
冰片 50g
蔗糖 50g
蜂蜜 100mL
苯甲酸 20g
制成 1000瓶
二、制备工艺
称取葛根素200g,麝香100g,冰片50g,蔗糖50g,蜂蜜100mL,苯甲酸20g,加水至10000mL,搅拌均匀,调节pH值为7.0~7.5,静置,滤过,灌装于10mL玻璃瓶中,灭菌,即得成品1000瓶。
实施例7:复方葛根素胶囊的制备
一、处方:
葛根素 150g
冰片 80g
淀粉 70g
微粉硅胶 适量
硬脂酸镁 适量
4%聚维酮K30的30%乙醇溶液 适量
制成 1000粒
二、制备工艺:
称取葛根素150g,冰片80g粉碎过100目筛,淀粉、微粉硅胶、硬脂酸镁郭60目筛。将主药与淀粉置于混合机中混匀,加入4%聚维酮K30的30%乙醇溶液,搅拌成型,制粒,在60℃干燥至水分低于5%,干颗粒40目整粒,加入微粉硅胶和硬脂酸镁混合混匀,测定颗粒含量,装胶囊,即得成品1000粒。
实施例8:复方葛根素颗粒的制备
一、处方:
葛根素 180g
麝香 80g
冰片 150g
蔗糖 1200g
淀粉 适量
阿司帕坦 适量
制成 1000袋
二、制备工艺:
称取葛根素180g,麝香80g,冰片150g粉碎过60目筛备用。称取蔗糖1200g过60目筛,淀粉过80目筛与主药于混合机中混合均匀,用含阿司帕坦的50%乙醇溶液制软材,制粒,70℃鼓风赶燥至水分小于1%。干颗粒分别过10目筛和80目筛,混匀。测定颗粒中主药含量,分装,即得成品1000包。
实施例9:本发明所制的复方葛根素滴丸与单味葛根素滴丸在生物利用度比较的动物试验结果如下所示:
其中试验时所用的材料为昆明小鼠,示踪剂为14C,标记物为葛根素;采用灌胃的形式进行给药;剂量分别为50mg/kg;给药后每2个小时断头处死一八小鼠,以时间为横坐标,以小鼠血液中的示踪剂为纵坐标;其中AUC1为复方葛根素滴丸示踪物浓度时相曲线下的面积,AUC2为单味葛根素滴丸示踪物浓度时相曲线下的面积;AUC1∶AUC2=1.2,说明本发明的复方葛根素滴丸的生物利用度的确比单味葛根素滴丸的生物利用度高。
实施例10:治疗脑血栓方面:建立模型为降低血流速度方法制备大鼠实验性血栓模型。动物使用的是豚鼠,由浙江(中科院动物实验中心)提供。
模型的建立方法:随机抽取体重为250-300g的豚鼠200只,3%戊巴比妥钠(20mg/kg)腹腔注射麻醉,开腹,分离腹主动脉和右骼总动脉,将一根前端粗糙的塑料管(直径约0.8mm),从右骼总动脉旋转插入至腹主动脉。然后拔管并结扎右骼总动脉,在腹主动脉辅一自制的弧形动脉夹,缝合、用青霉素注射防止感染,模型建立。一直检测血栓形成情况,发现血栓出现率和血栓的形成长度均达到要求。
把经过手术豚鼠分为2小组,每组100只,第I组注射本发明的复方葛根素注射液,其中剂量为10mg/kg,每天一次,连续15天静脉注射给药;第II组作为对照组采用单味的葛根素注射液,其中剂量为10mg/kg,每天一次,连续15天静脉注射给药;其结果如表1所示:
从表1的统计学意义可以看出本发明的复方葛根素注射液在治疗血栓方面明显好于对照组(p<0.01)
表1两种药物治疗结果比较
组别 | 血栓溶解数 | 血栓未溶解数 | 合计 |
第I组第II组合计 | 8529114 | 1 57186 | 100100200 |
注:本发明的复方葛根素注射液组和对照组相比P<0.01。说明本发明的复方葛根素注射液组与对照组相比有明显差别。
此外注射本发明复方葛根素注射液血栓溶解的速度也比较快,在注射本发明复方葛根素注射液后15分钟后就见效,药效长达11小时,由此说明本发明复方葛根素制剂在治疗脑血栓方面有很好的疗效。
实施例11、治疗脑干缺血方面:建立模型为非开颅术脑干缺血模型。动物使用的是SD大鼠,由浙江(中科院动物实验中心)提供。
模型的建立方法:随机抽取220g~280g的SD大白鼠200只,用3%戊巴比妥钠(20mg/kg)腹腔注射麻醉,固定在小动物手术台上,用手术缝线挂于大鼠的上门齿上,拉直颈部并固定,在两胸锁关节间沿正中线切25mm的切口,分离附在锁骨上的肌肉并结扎止血;再去除两侧的锁骨,继续逐层分离肌肉,血管至臂神经丛,沿下分支寻找并分离椎动脉3~4mm,用电位仪记录脑干听觉诱发电位;然后用微型止血夹夹闭椎动脉,同时用电位仪,记录听觉诱发电位的变化,证明脑干确实出现缺血的听觉诱发电话时,将切口表层缝合,但要暴露微型止血夹(便于让椎动脉再通)模型建立。
把经过手术SD大鼠分为两组,每组100只,第I组使用本发明的复方葛根素注射液,其中剂量为10mg/kg,每天一次,连续30天静脉注射给药;第II组作为对照组采用单味的葛根素注射液,其中剂量为10mg/kg,每天一次,连续30天静脉注射给药;通过表2观察脑干听觉诱发电位可以看出第I组对脑干缺血的有效率明显高于第II组
表2:治疗后听觉诱发电位的改变
组别 | 显效数 | 显效率 | 有效数 | 无效数 | 有效率 |
第I组(n=100)第II组(n=100) | 3416 | 34.0%16.0% | 5432 | 1252 | 88.0%48.0% |
注:治疗结果表明:本发明的复方葛根素制剂组在治疗脑干缺血方面比对照组的效果明显好。此外注射本发明复方葛根素注射液血栓溶解的速度也比较快,在注射本发明复方葛根素注射液后10分钟后就见效,药效长达11小时,由此说明本发明复方葛根素制剂在治疗脑干缺血方面有很好的疗效。
本发明中所描述的具体实施例仅仅是对本发明精神作举例说明。本发明所属技术领域的技术人员可以对所描述的具体实施例做各种各样的修改或补充或采用类似的方式替代,但并不会偏离本发明的精神或者超越所附权利要求书所定义的范围。
尽管对本发明已作出了详细的说明并引证了一些具体实例,但是对本领域熟练技术人员来说,只要不离开本发明的精神和范围可作各种变化或修正是显然的。
Claims (1)
1.一种复方葛根素制剂,其特征在于所述的制剂为注射剂,其处方如下:
葛根素 200g
麝香 30g
羟丙基倍他环糊精 15g
制成 1000支,
其制备工艺如下:
称取麝香30g,加入羟丙基倍他环糊精15g助溶,加入葛根素200g混匀,加入注射用水至8000ml,温热溶解,加入活性炭脱色,去除热源,用砂棒滤去活性炭,加入注射用水至10000ml,调节pH值为6.0~7.0,检测其含量,合格时,经0.22μm微孔滤膜精滤,罐装于10ml安瓶中,灭菌30分钟,冷却后进行灯检,再经检验合格后,得到水针成品。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610049229XA CN101007014B (zh) | 2006-01-24 | 2006-01-24 | 一种复方葛根素制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200610049229XA CN101007014B (zh) | 2006-01-24 | 2006-01-24 | 一种复方葛根素制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101007014A CN101007014A (zh) | 2007-08-01 |
CN101007014B true CN101007014B (zh) | 2010-10-13 |
Family
ID=38695824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200610049229XA Expired - Fee Related CN101007014B (zh) | 2006-01-24 | 2006-01-24 | 一种复方葛根素制剂 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101007014B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042603B (zh) * | 2014-05-28 | 2019-11-05 | 西北农林科技大学 | γ-氨基丁酸在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用 |
CN104042602A (zh) * | 2014-05-28 | 2014-09-17 | 西北农林科技大学 | 谷氨酸钠在葛根素注射剂中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1389211A (zh) * | 2002-07-18 | 2003-01-08 | 北京四环科宝制药有限公司 | 葛根素注射剂及其制备工艺 |
CN1394603A (zh) * | 2002-08-09 | 2003-02-05 | 陕西镇坪制药厂 | 羟乙葛根素在制备治疗脑血管病新药中的应用 |
-
2006
- 2006-01-24 CN CN200610049229XA patent/CN101007014B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1389211A (zh) * | 2002-07-18 | 2003-01-08 | 北京四环科宝制药有限公司 | 葛根素注射剂及其制备工艺 |
CN1394603A (zh) * | 2002-08-09 | 2003-02-05 | 陕西镇坪制药厂 | 羟乙葛根素在制备治疗脑血管病新药中的应用 |
Non-Patent Citations (5)
Title |
---|
CN 1389211 A,实施例5. |
刘洋,等.冰片的药理实验研究概况.天津中医药20 8.2003,20(8),85-87. |
刘洋等.冰片的药理实验研究概况.天津中医药20 8.2003,20(8),85-87. * |
卢薇,等.中药对血脑屏障作用的实验研究进展.中西医结合心脑血管杂志3 1.2005,3(1),60-61. |
卢薇等.中药对血脑屏障作用的实验研究进展.中西医结合心脑血管杂志3 1.2005,3(1),60-61. * |
Also Published As
Publication number | Publication date |
---|---|
CN101007014A (zh) | 2007-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3505161B1 (en) | Sublingual pharmaceutical composition of edaravone and (+)-2-borneol | |
KR101891505B1 (ko) | 혈구 감소를 예방 또는 치료하기 위한 약물의 제조에 있어서의 안히드로이카리틴의 용도 | |
WO2019206159A1 (zh) | 绿原酸及其组合物在制备治疗肉瘤的药物中的用途 | |
CN113546089B (zh) | 1-乙基-3,7-二甲基黄嘌呤在制备治疗肺炎药物中的应用 | |
CN105998019A (zh) | 一种治疗脑胶质瘤的药物组合物及其用途 | |
CN106074463A (zh) | 大麻二酚在制备治疗痛风性关节炎药物中的应用 | |
CN102342931B (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
CN101007014B (zh) | 一种复方葛根素制剂 | |
CN101219128A (zh) | 具有改善溶出性能的右旋布洛芬药物组合物及其制备方法 | |
CN101757443A (zh) | 一种治疗血友病的中药制剂 | |
CN100563682C (zh) | 一种由山楂叶与红景天制成的药物组合物及其制备方法 | |
CN106943390B (zh) | 马钱苷元在制备预防或治疗心律失常药物中的应用 | |
CN101327215B (zh) | 一种含有原小檗碱型生物碱的药物组合物 | |
CN101081227B (zh) | 甘草酸二铵的组合物 | |
CN1444948B (zh) | 灯盏花素脂质体及其制备方法 | |
CN109364071A (zh) | 一种促唾液分泌治疗口腔干燥综合征的药物及用途 | |
CN102451170B (zh) | 盐酸格拉司琼冻干片及其制备方法 | |
CN1994345B (zh) | 一种治疗心脑血管疾病的复方中药制剂 | |
CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
CN110693882A (zh) | 一种舌下用药物组合物 | |
CN107998117B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
CN100396295C (zh) | 一种治疗病毒性肝炎的药物 | |
CN1846721B (zh) | 七叶神安口腔崩解片及其制备方法 | |
CN113368098A (zh) | 淫羊藿苷元在制备血友病防治药物中的用途 | |
CN1762341A (zh) | 治疗心脑血管疾病、肝脏疾病的丹参酚酸复合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101013 Termination date: 20120124 |